InsidersTradesSigma
Track the 리가켐바이오 share price and the full insider trade history of the company, a listed equity based in South Korea. Shares trade on KR KR, under the oversight of DART (FSS). Operating in the Health Care sector, 리가켐바이오 has published 6 insider filings. Market capitalisation: €3,217.6bn. The latest transaction was disclosed on 24 July 2026 (Purchase). Among the most active insiders: PANORIONCORP.LIMITED. All data is openly available.
Analysts rate 리가켐바이오 Buy (bullish), based on 6 analysts. Average price target: ₩221,667.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
6 of 6 declarations
LigaChemBio is a company specializing in the healthcare and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative solutions for disease treatment.